CARLSBAD, Calif.--(BUSINESS WIRE)--May. 26, 2009-- Applied Biosystems, a division of Life Technologies Corporation (NASDAQ:LIFE), today announced the expansion of its industry-leading portfolio of capillary electrophoresis sequencing systems with the introduction of two new lines of genetic analyzers. The 3500 Series, for research use only, will be available worldwide. The 3500 Dx Series is intended for clinical use and will initially be launched in specific countries within the European Union. Both platforms will provide state-of-the-art advancements in CE sequencing systems, setting significant new standards for throughput, data quality and ease of use.

Currently, researchers use DNA sequencing as a method for identifying genetic variation. Scientists participating in an early evaluation of the technology are interested in studying the most widely recognized human genetic disorders, such as those caused by extra or missing chromosomes, as well as a broad spectrum of other disorders. Some of these data were presented at the European Society of Human Genetics meeting in Vienna, Austria.

3500 Dx Series Genetic Analyzers

The 3500 Dx Series Genetic Analyzers are intended for use by trained operators in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility. This system will be distributed and used in specific European countries only, including France, Germany, Italy, the Netherlands, Spain, Sweden, and the United Kingdom. It represents the first CE system and accessories to comply with the European Union In Vitro Diagnostic Medical Devices Directive 98/79/EC. Commercial launch of the 3500 Dx Series Systems is anticipated in August 2009.

3500 Series Genetic Analyzers (For Research Use Only)

The 3500 Series enables researchers to run up to 1,100 sequencing or 1,200 genotyping samples per day. It features novel consumable designs, incorporating the ability to track key information with radio frequency identification (RFID) tags, new optical and thermal systems designs, and redesigned data collection and analysis software, which enables easy generation of cost-effective analyses and high-quality data. The 3500 Series Systems are for research use only, and are anticipated to be commercially available in August 2009.

Dr. Emiliano Giardina, Professor of Medical Genetics, University of Rome “Tor Vergata”

“The 3500 Series of sequencers will support a wide variety of genetic research in Europe. This technology may also ease the analysis and create standardization for genetics laboratories, which will help alleviate the different quality of results that stem from varying technologies and chemistries.”

Dr. Roland Achmann, MVZ genteQ

“The results we obtained with the 3500 Series were of good quality and absolutely comparable with the data we receive with our current capillary electrophoresis platform. In addition to quality results, the new system also offers certain features that allow us to shorten the time to results, which is a very important advantage in our continuing effort to optimize our analysis workflow.”

Kip Miller, President of Life Technologies’ Genetic Systems Division

“The introduction of these two new lines of CE sequencing platforms further demonstrates Life Technologies’ commitment to innovation in DNA sequencing and our desire to broaden the applications of this technology. These highly automated and simplified solutions respond to the requirements of scientists and European clinicians for advanced genomic analysis technologies.”

Resources

• 3500 Series Genetic Analyzers

The 3500 Series and 3500 Dx Series are part of a broader portfolio of advanced genomic technologies that are built upon Applied Biosystems’ legacy of providing platforms that are recognized for proven technology, reliability and performance. The new genetic analyzers provide an integrated solution that combines the instrument with Applied Biosystems reagents, consumables, software, service and support.

Applied Biosystems Products

Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. Applied Biosystems, along with Invitrogen – a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics – is part of Life Technologies. Together, Applied Biosystems and Invitrogen provide the broadest portfolio of RNA analysis tools available from a single company. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world. For more information, please visit: www.appliedbiosystems.com and www.invitrogen.com.

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

The 3500 Series systems are for research use only. Not for use in diagnostic procedures.

Copyright 2009. Life Technologies Corporation. All rights reserved. AB (Design), and Applied Biosystems are registered trademarks of Life Technologies or its subsidiaries in the United States and/or certain other countries.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5972343&lang=en

Source: Life Technologies Corporation

Life Technologies Corporation
Media
Renaldo Juanso, 650-638-5354
renaldo.juanso@lifetech.com
Lauren Lum, 650-638-6916
lauren.lum@lifetech.com
Investors
Amanda Clardy, 760-603-7200
amanda.clardy@lifetech.com